- Home
- PHAR vs AEVA Comparison
PHAR vs AEVA Comparison
Compare PHAR & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- AEVA
- Stock Information
- Founded
- PHAR 1988
- AEVA 2019
- Country
- PHAR Netherlands
- AEVA United States
- Employees
- PHAR N/A
- AEVA N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- AEVA Auto Parts:O.E.M.
- Sector
- PHAR Health Care
- AEVA Consumer Discretionary
- Exchange
- PHAR Nasdaq
- AEVA Nasdaq
- Market Cap
- PHAR 951.7M
- AEVA 902.9M
- IPO Year
- PHAR N/A
- AEVA N/A
- Fundamental
- Price
- PHAR $13.86
- AEVA $17.11
- Analyst Decision
- PHAR Strong Buy
- AEVA Strong Buy
- Analyst Count
- PHAR 3
- AEVA 5
- Target Price
- PHAR $30.00
- AEVA $20.80
- AVG Volume (30 Days)
- PHAR 13.2K
- AEVA 2.7M
- Earning Date
- PHAR 10-23-2025
- AEVA 11-05-2025
- Dividend Yield
- PHAR N/A
- AEVA N/A
- EPS Growth
- PHAR N/A
- AEVA N/A
- EPS
- PHAR N/A
- AEVA N/A
- Revenue
- PHAR $339,836,000.00
- AEVA $13,825,000.00
- Revenue This Year
- PHAR $16.63
- AEVA $110.19
- Revenue Next Year
- PHAR $6.77
- AEVA $96.22
- P/E Ratio
- PHAR N/A
- AEVA N/A
- Revenue Growth
- PHAR 22.44
- AEVA 111.39
- 52 Week Low
- PHAR $7.31
- AEVA $2.52
- 52 Week High
- PHAR $17.08
- AEVA $38.80
- Technical
- Relative Strength Index (RSI)
- PHAR 51.52
- AEVA 56.31
- Support Level
- PHAR $13.63
- AEVA $14.82
- Resistance Level
- PHAR $15.27
- AEVA $16.59
- Average True Range (ATR)
- PHAR 0.98
- AEVA 1.33
- MACD
- PHAR -0.17
- AEVA 0.58
- Stochastic Oscillator
- PHAR 16.68
- AEVA 78.56
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.